Increased myocardial fibrosis and left ventricular dysfunction in Cushing’s syndrome

Kai Hang Yiu1,2,*, Nina Ajmone Marsan1,3,*, Victoria Delgado1, Nienke R Biermasz4, Eduard R Holman1, Johannes W A Smit4, Richard A Feelders5, Jeroen J Bax1 and Alberto M Pereira4

1Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands, 2Cardiology Division, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China, 3The Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands, 4Department of Endocrinology and Metabolic Disease, Leiden University Medical Center, 2300 RC Leiden, The Netherlands and 5Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

*(K H Yiu and N Ajmone Marsan contributed equally to this work)

Abstract

Objective: Active Cushing’s syndrome (CS) is associated with cardiomyopathy, characterized by myocardial structural, and ultrastructural abnormalities. The extent of myocardial fibrosis in patients with CS has not been previously evaluated. Therefore, the objective of this study was to assess myocardial fibrosis in CS patients, its relationship with left ventricular (LV) hypertrophy and function, and its reversibility after surgical treatment.

Design and methods: Fifteen consecutive CS patients (41 ± 12 years) were studied together with 30 hypertensive (HT) patients (matched for LV hypertrophy) and 30 healthy subjects. Echocardiography was performed in all patients including i) LV systolic function assessment by conventional measures and by speckle tracking-derived global longitudinal strain, ii) LV diastolic function assessment using E/E0, and iii) myocardial fibrosis assessment using calibrated integrated backscatter (IBS). Echocardiography was repeated after normalization of cortisol secretion (14 ± 3 months).

Results: CS patients showed the highest value of calibrated IBS (−15.1 ± 2.5 dB) compared with HT patients (−20.0 ± 2.6 dB, P < 0.01) and controls (−23.8 ± 2.4 dB, P < 0.01), indicating increased myocardial fibrosis independent of LV hypertrophy. Moreover, calibrated IBS in CS patients was significantly related to both diastolic function (E/E0, r = 0.79, P < 0.01) and systolic function (global longitudinal strain, r = 0.60, P = 0.02). After successful surgical treatment, calibrated IBS normalized (−21.0 ± 3.8 vs −15.1 ± 2.5 dB, P < 0.01), suggestive of regression of myocardial fibrosis.

Conclusions: Patients with CS have increased myocardial fibrosis, which is related to LV systolic and diastolic dysfunction. Successful treatment of CS normalizes the extent of myocardial fibrosis. Therefore, myocardial fibrosis appears to be an important factor in the development and potential regression of CS cardiomyopathy.

Introduction

Patients with Cushing’s syndrome (CS) have an increased risk for cardiovascular diseases (1). Previous studies using echocardiography have demonstrated that CS is associated with a specific cardiomyopathy characterized by left ventricular (LV) hypertrophy, increased relative wall thickness (2), and both diastolic (3) and systolic dysfunction (4, 5). These alterations are related to the endogenous glucocorticoid excess, which leads to an increase in blood pressure via the stimulation of both mineralocorticoid (MR) and glucocorticoid receptors (GR) (6–8) but also through the activation of the renin–angiotensin system components and through the effect of cortisol on peripheral and systemic vasculature (9–11). These mechanisms are also proposed to be crucial in the development of myocardial fibrosis and significant structural damage (12, 13). However, myocardial tissue alterations, and in particular myocardial fibrosis in CS patients, have not been previously evaluated.

Ultrasonic integrated backscatter (IBS) derived by two-dimensional (2D) echocardiography provides information on myocardial ultrasound reflectivity, which increases when myocardial fibrosis increases (14, 15). Fibrosis assessment using IBS has been validated in a direct comparison with histological findings (14) and it has been used in detecting increased myocardial fibrosis in several cardiovascular diseases, including hypertensive (HT) patients (16, 17).
Therefore, we hypothesized that i) myocardial fibrosis in CS, as measured by IBS, would be increased and ii) that the extent of myocardial fibrosis would be significantly related to LV function. Finally, we hypothesized that, if this would be the case, successful treatment of CS would lead to regression or even normalization of the extent of myocardial fibrosis.

Subjects and methods

Patient population

The patient population consisted of 15 consecutive CS patients, who were referred to the Endocrinology Department of our Center and whose clinical and echocardiographic characteristics have been previously described (5). Briefly, the underlying cause of CS was an ACTH-producing pituitary adenoma in 12 patients, while in three patients CS was ACTH independent. The diagnosis of CS was made on clinical grounds in combination with the following biochemical criteria: increased 24 h urinary free cortisol excretion (> 220 nmol), failure of serum cortisol to suppress after low-dose dexamethasone (one evening dose of 1 mg), and loss of diurnal rhythm. In case of ACTH-dependent CS, the suppression of serum cortisol during a 7 h i.v. dexamethasone suppression test (5, 18) was also evaluated together with the response of serum cortisol and ACTH on i.v. corticotropin-releasing hormone stimulation (19).

All patients underwent surgical treatment (transsphenoidal adenomectomy or unilateral or bilateral adrenalectomy) followed by pituitary irradiation when necessary (n = 6). After treatment, all patients were assessed at least twice yearly by an endocrinologist, with adequate evaluation and treatment of possible pituitary hormone deficiencies. Patients were considered in remission according to normal 24 h urinary cortisol excretion rates (< 80 µg/24 h or < 220 nmol/24 h) and normal overnight suppression of serum cortisol (< 1.8 µg/dl or < 50 nmol/l) after 1 mg dexamethasone.

Study protocol

All patients underwent transthoracic echocardiography at baseline and at least 1 year and maximum 18 months (median 14 ± 2.8 months) after obtaining definite biochemical remission either by surgery alone or by surgery followed by radiotherapy. The echocardiographic examination included

i) conventional measurements of LV size and LV systolic and diastolic function;

ii) 2D speckle tracking strain analysis, which is a highly sensitive echocardiographic technique for the assessment of subtle changes of LV systolic function (5); and

iii) calibrated IBS, for the assessment of myocardial fibrosis.

By using these echocardiographic techniques, the relationship between the changes in LV function and in myocardial fibrosis after surgical treatment could be addressed.

For comparison, 30 healthy individuals (2:1 ratio to CS patients) matched for age and gender were consecutively selected as a control group from an existing echocardiographic database with this information. These subjects were referred for atypical chest pain, palpitations, or syncope without murmur and showed normal structural heart on echocardiography. Furthermore, they were carefully screened to exclude the presence of HT (systolic blood pressure < 130 mmHg and/or diastolic blood pressure < 90 mmHg) or any history of anti-HT treatment.

The study was approved by the local institutional ethics committee, and written informed consent was obtained from all patients and subjects.

Echocardiography

All patients were imaged in the left lateral decubitus position using a commercially available system (Vingmed Vivid 7, General Electric Vingmed Ultrasound, Horten, Norway). Images were obtained using a 3.5 MHz transducer and digitally stored in cine-loop format; offline analysis was performed using EchoPAC version 108.1.5 (GE-Vingmed Ultrasound). From the standard apical views (4- and 2-chamber), LV volumes and ejection fraction were calculated using Simpson’s biplane method (14). LV end-diastolic and end-systolic diameter and LV septum and posterior wall thickness were measured from M-mode recordings obtained at the parasternal long-axis view. In addition, relative wall thickness was calculated as the ratio between end-diastolic posterior wall thickness and LV diameter (20), and LV mass index was calculated by Devereux’s formula and indexed to body surface area (21).

Diastolic function was evaluated by measuring transmural flow E-wave velocity (E) and A-wave velocity (A) using pulse-wave Doppler recordings, and the E/A ratio was calculated (22). In addition, as an estimate of LV filling pressure, early diastolic peak velocity (E’) was measured at the septal level of mitral valve annulus from tissue Doppler imaging data, and E/E’ ratio was derived (23).

2D speckle tracking strain analysis

The measure of global longitudinal, radial, and circumferential strains using speckle tracking has
anteroseptal and posterior wall and the mean value of the two walls was used. Examples of calibrated IBS measurement in a normal subject and a CS patient are shown in Fig. 1. The intra- and inter-observer agreements for calibrated IBS (calculated by re-measuring the entire patient population) were 0.91 and 0.92, respectively, using intra-class correlation coefficients.

**Statistical analysis**

Continuous variables are presented as mean ± s.d. Categorical data are presented as frequencies and percentages. One-way ANOVA with post hoc test by Bonferroni was used to examine differences among groups. Pearson’s correlation test was used to evaluate the correlation between calibrated IBS and other echocardiographic parameters. Mean calibrated IBS was compared before and after surgical treatment of CS using paired t-test. All statistical analyses were performed using the statistical package SPSS for windows (Version 15.0, SPSS, Chicago, IL, USA). A P value < 0.05 was considered to be statistically significant.

**Results**

**Baseline clinical characteristics**

Baseline clinical characteristics of CS patients, HT patients, and healthy controls are shown in Table 1. According to the matching criteria, age was similar between controls and CS patients, who were both significantly younger than the HT patients. All three groups had similar gender distribution. Body mass index was significantly higher in HT and CS patients.

| Table 1 Baseline clinical characteristics of healthy controls, HT and CS patients. |
|-----------------|----------------|----------------|
| **Controls** (n = 30) | **HT patients** (n = 30) | **CS patients** (n = 15) |
| Age (years) | 40 ± 8 | 53 ± 13* | 41 ± 12† |
| Gender – male (%) | 44 (67) | 15 (50) | 6 (40) |
| BMI (kg/m²) | 23.8 ± 3.1 | 27.0 ± 5.4* | 27.4 ± 4.7* |
| SBP (mmHg) | 120 ± 9 | 138 ± 12* | 135 ± 13* |
| DBP (mmHg) | 75 ± 10 | 86 ± 9* | 88 ± 12* |
| ACEI (%) | – | 6 (20) | 5 (33) |
| ARB (%) | – | 4 (13.3) | 1 (6.7) |
| Calcium channel blockers (%) | – | 5 (16.7) | 1 (6.7) |
| Diuretics (%) | – | 6 (20) | 1 (6.7) |
| β-Blockers (%) | – | 10 (33.3) | 3 (20) |
| Anti-diabetics/insulin (%) | – | 5 (33) | – |

**Note:** BMI, body mass index; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure; ANOVA P values < 0.05 are in bold; *Significant differences with controls; †Significant differences with HT patients.
compared with healthy controls. As expected, CS and HT patients had higher values of systolic and diastolic blood pressure compared with healthy subjects. Of note, 45% of CS patients received anti-HT medication, including angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, and β-blockers.

**Baseline echocardiography and 2D speckle tracking strain analysis**

According to the matching criteria, HT and CS patients showed comparable end-diastolic septal thickness and LV mass index, which were larger compared with normal subjects (Table 2). No significant differences in LV dimensions and LV ejection fraction were observed between the three groups. Diastolic function, as measured by E/A ratio and E/E' ratio, was significantly impaired in CS and HT patients compared with the control group.

Speckle tracking strain analysis for the assessment of cardiac systolic function showed significant impairment of global longitudinal strain in the HT and CS groups compared with controls (Table 2). In particular, global longitudinal strain was significantly lower in the CS group compared with the HT group. Global circumferential strain was significantly lower in CS patients, while no differences were noted between controls and HT patients. Global radial strain showed no significant differences among the three groups.

**Myocardial fibrosis assessment with calibrated IBS**

Patients with CS showed the highest mean calibrated IBS (-15.1 ± 2.5 dB) compared with HT patients (-20.0 ± 2.6 dB, *P* < 0.01) and controls (-23.8 ± 2.4 dB, *P* < 0.01; Fig. 2), suggesting an increased myocardial fibrosis. Moreover, mean calibrated IBS was significantly higher in HT patients compared with healthy subjects (*P* < 0.01).

Mean calibrated IBS in CS patients was significantly related to LV diastolic function, namely with E/E' ratio (*r* = 0.79, *P* < 0.01), and LV systolic function, i.e. global longitudinal strain (*r* = 0.60, *P* = 0.02; Table 3). In turn, no significant relation was observed with global circumferential or radial strain, age, blood pressure, or LV mass index.

**Follow-up of the patient with CS after surgery**

All patients were in biochemical remission for at least 1 year at follow-up, but six patients remained glucocorticoid dependent after surgery (hydrocortisone dose was on average 20 mg/day divided into three dosages). The number of patients using anti-HT or anti-diabetic medication was on average 20 mg/day divided into three dosages).

---

**Table 2** Baseline echocardiographic characteristics of controls, HT and CS patients.

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 30)</th>
<th>HT patients (n = 30)</th>
<th>CS patients (n = 15)</th>
<th>ANOVA P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV end-diastolic diameter (cm)</td>
<td>4.7 ± 0.3</td>
<td>4.5 ± 0.3</td>
<td>5.0 ± 0.6</td>
<td>0.27</td>
</tr>
<tr>
<td>LV end-systolic diameter (cm)</td>
<td>3.1 ± 0.3</td>
<td>2.9 ± 0.2</td>
<td>3.2 ± 0.5</td>
<td>0.31</td>
</tr>
<tr>
<td>LV ejection fraction (%)</td>
<td>60 ± 4</td>
<td>62 ± 5</td>
<td>59 ± 9</td>
<td>0.21</td>
</tr>
<tr>
<td>End-diastolic septal thickness (cm)</td>
<td>0.9 ± 0.1</td>
<td>1.2 ± 0.3*</td>
<td>1.3 ± 0.2*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>LV mass index (g/m²)</td>
<td>79.6 ± 16.1</td>
<td>124.1 ± 35.2*</td>
<td>125.6 ± 37.2*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Relative wall thickness</td>
<td>0.37 ± 0.06</td>
<td>0.49 ± 0.09*</td>
<td>0.48 ± 0.09*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>E wave velocity (m/s)</td>
<td>78.8 ± 12.6</td>
<td>73.1 ± 14.1</td>
<td>58.2 ± 12.6*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>A wave velocity (m/s)</td>
<td>58.6 ± 14.2</td>
<td>73.2 ± 16.8*</td>
<td>65.0 ± 22.0</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>1.4 ± 0.5</td>
<td>1.1 ± 0.3*</td>
<td>1.0 ± 0.4*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>E' velocity (cm/s)</td>
<td>10.0 ± 2.4</td>
<td>8.3 ± 3.4*</td>
<td>6.0 ± 2.4*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>E/E' ratio</td>
<td>8.0 ± 1.9</td>
<td>10.3 ± 4.3*</td>
<td>10.9 ± 3.8*</td>
<td>0.01</td>
</tr>
<tr>
<td>Global longitudinal strain (%)</td>
<td>−21.4 ± 1.9</td>
<td>−19.3 ± 2.2*</td>
<td>−15.4 ± 1.9*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Global circumferential strain (%)</td>
<td>−20.9 ± 2.5</td>
<td>−20.7 ± 2.1</td>
<td>−16.5 ± 3.5*</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Global radial strain (%)</td>
<td>38.8 ± 13.7</td>
<td>38.6 ± 14.5</td>
<td>33.8 ± 12.9</td>
<td>0.53</td>
</tr>
</tbody>
</table>

A, trans-mitral A-wave velocity; E, trans-mitral E-wave velocity; E', early diastolic peak velocity; LV, left ventricular. *Significant differences with controls; †Significant differences with HT patients. ANOVA P values < 0.05 are in bold.
As described previously (5), after surgical treatment and complete biochemical remission, a significant regression of LV hypertrophy with a reduction in end-diastolic septum thickness (1.3 ± 0.2 vs 1.0 ± 0.2 cm, P < 0.01), LV mass index (126 ± 37 vs 98 ± 31 g/m², P = 0.01), and relative wall thickness (0.48 ± 0.09 vs 0.41 ± 0.08 cm, P = 0.04) was observed in patients with CS. Furthermore, significant improvements were observed in E’ velocity (6.0 ± 2.4 vs 8.2 ± 2.6 cm/s, P = 0.04), global longitudinal strain (-15.4 ± 1.9 vs -18.9 ± 2.1%, P < 0.01), and global circumferential strain (-16.5 ± 3.5 vs -20.3 ± 3.9%, P < 0.01), but not in global radial strain (33.8 ± 12.8 vs 30.6 ± 11.6%, P = 0.75).

A significant reduction of IBS to values comparable to healthy controls was observed at follow-up (−15.1 ± 2.5 vs −21.0 ± 3.8 dB, P < 0.01), suggestive for a decrease in myocardial fibrosis after successful surgical treatment of CS. (Fig. 3).

**Discussion**

The results of the current study demonstrate that myocardial fibrosis is significantly increased in active, untreated patients with CS compared with both healthy subjects and HT patients, pointing toward a direct effect of cortisol excess on myocardial fibrosis, independent of LV hypertrophy and blood pressure. Furthermore, in patients with CS, mean calibrated IBS significantly correlated with LV systolic (global longitudinal strain) and diastolic function (E/E’), indicating that myocardial fibrosis per se affects cardiac function. Finally, the extent of myocardial fibrosis normalized upon successful treatment of CS. Therefore, myocardial fibrosis appears to be an important factor both in the development and in the regression of the cardiomyopathy as seen in CS.

Cardiac involvement in patients with CS is mainly characterized by the presence of LV hypertrophy and concentric remodeling (2, 4). These structural abnormalities can be partially explained by the rise in blood pressure, but the most important role is attributed to glucocorticoid excess, which directly activates some of the components of the rennin–angiotensin system (25, 26) and in particular enhances angiotensin-II responsiveness of the myocytes (27). More importantly, control of both the MRs and the GRs appears to be critical in the regulation and development of myocardial fibrosis (28, 29). Under physiological circumstances, circulating cortisol levels are more than 100-fold higher than aldosterone. Because MRs have equal affinity for aldosterone and cortisol, selective activation of MRs by aldosterone in epithelial tissue and vascular smooth muscle cells is achieved by co-expression of the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) that converts endogenous cortisol to its MR-inactive cortisone. Under normal circumstances, 11βHSD2 is not expressed in cardiomyocytes (30) and therefore MRs.

**Table 3** Correlation coefficient (r) between mean calibrated integrated backscatter (IBS) and clinical and echocardiographic parameters in patients with CS.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>r</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.27</td>
<td>0.33</td>
</tr>
<tr>
<td>Body mass index</td>
<td>−0.40</td>
<td>0.13</td>
</tr>
<tr>
<td>Ureane free cortisol</td>
<td>0.32</td>
<td>0.36</td>
</tr>
<tr>
<td>SBP</td>
<td>−0.42</td>
<td>0.12</td>
</tr>
<tr>
<td>DBP</td>
<td>−0.27</td>
<td>0.33</td>
</tr>
<tr>
<td>LV mass index</td>
<td>−0.07</td>
<td>0.81</td>
</tr>
<tr>
<td>LV ejection fraction</td>
<td>−0.28</td>
<td>0.34</td>
</tr>
<tr>
<td>LV end-diastolic diameter</td>
<td>−0.19</td>
<td>0.72</td>
</tr>
<tr>
<td>E wave velocity</td>
<td>0.16</td>
<td>0.55</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>−0.29</td>
<td>0.29</td>
</tr>
<tr>
<td>E’ velocity</td>
<td>−0.63</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>E/E’ ratio</td>
<td>0.79</td>
<td>0.02</td>
</tr>
<tr>
<td>Global longitudinal strain</td>
<td>0.60</td>
<td>0.02</td>
</tr>
<tr>
<td>Global circumferential strain</td>
<td>0.37</td>
<td>0.19</td>
</tr>
<tr>
<td>Global radial strain</td>
<td>−0.39</td>
<td>0.17</td>
</tr>
</tbody>
</table>

For abbreviations, see Tables 1 and 2. P values < 0.05 are in bold.

**Figure 3** Mean calibrated integrated backscatter (IBS) in patients with Cushing’s syndrome (CS) before (baseline) and after surgical treatment (follow-up). The shaded area represents the normal range of mean calibrated IBS, derived from the control group as the mean value ± 2 s.d. Upon successful surgical treatment, the mean calibrated IBS in CS patients significantly decreased (P < 0.01) and reached the range of normal values, suggesting the reversibility of myocardial fibrosis.
Collagen deposition increases myocardial acoustic impedance and reflectivity, which can be detected by calibrated IBS (14). This technique has been previously used to evaluate myocardial fibrosis in several cardiovascular diseases (16, 32). In a study of 117 HT patients referred for an echocardiographic evaluation, Di Bello et al. (17) showed that HT patients had higher IBS values than normal controls and that IBS was significantly correlated with the severity of LV hypertrophy. This study demonstrated that patients with active CS have increased myocardial fibrosis as assessed by calibrated IBS, when compared with both normal subjects and HT patients with similar LV wall thickness and mass index. These findings are in agreement with a direct deleterious effect of cortisol excess on the myocardium, superimposed and independent of elevated blood pressure, and LV hypertrophy.

Previous studies have shown the relationship between the extent of myocardial fibrosis and the degree of myocardial dysfunction in various cardiac diseases (16, 32). Shan et al. (33) demonstrated that in patients with coronary artery disease, reduced myocardial velocities and impaired LV relaxation assessed by echocardiography were inversely related to the percentage of interstitial fibrosis quantified on endomyocardial biopsies. Similarly, the results of the current study demonstrated that in patients with CS, myocardial fibrosis, as measured by IBS, was significantly related to both LV systolic function, assessed by global longitudinal strain, and to LV diastolic function. However, neither blood pressure nor LV mass index was significantly related to calibrated IBS. These observations point toward specific cortisol excess-induced effects on the development of myocardial fibrosis that, in turn, significantly contributes to the development of cardiac dysfunction, independent of LV hypertrophy. In particular, global longitudinal strain, reflecting myocardial shortening of the subendocardial layer, is highly sensitive to subtle changes in LV systolic function potentially mediated by increased myocardial fibrosis. Conversely, impairment of circumferential and radial strain showed to occur in a more advanced stage of cardiac involvement and to be less sensitive for the detection of subtle changes in LV function. Furthermore, myocardial fibrosis is also one of the main determinants of LV wall stiffness and therefore directly affects LV diastolic function, as measured by E/E’.

A significant reduction in LV mass, relative wall thickness, and improvement in both diastolic and systolic function has been shown after successful surgical treatment for CS (5). This study has also demonstrated that normalization of cortisol levels in patients with CS leads to a significant reduction of myocardial fibrosis detected by calibrated IBS. As previously shown in HT patients treated with rennin–angiotensin system antagonists (34, 35), reduction in angiotensin-II activity may i) significantly reduce myocardial collagen synthesis, as demonstrated by a drop in serum concentrations of procollagens (36) and ii) enhance collagen degradation (37), resulting in a significant regression of myocardial fibrosis. Accordingly, normalization of cortisol levels after successful treatment of CS should not only normalize the activity of some of the renin–angiotensin system components but also the regulation of tissue-specific MR and GR, resulting in reversal of increased myocardial fibrosis.

The assessment of the extent of myocardial fibrosis by calibrated IBS represents a novel approach to detect cardiac involvement in patients with CS, eventually before the occurrence of subtle myocardial dysfunction. Therefore, it might be used for patient management and monitoring. In addition, this study, prospectively evaluating patients with CS before and after successful treatment, represents a clinical model that confirms the significant effect of glucocorticoid excess on myocardial fibrosis.

In conclusion, patients with active CS have increased myocardial fibrosis, which is related to LV systolic and diastolic dysfunction. Successful treatment of CS normalizes the extent of myocardial fibrosis parallel to LV systolic and diastolic function. Whether these observations also apply to patients treated with exogenous corticosteroids for other, more prevalent diseases, like chronic obstructive pulmonary disease, or rheumatoid arthritis, still remains to be determined.

Declarations of interest

J J Bax receives grants from Biotronik, Lantheus medical imaging, Boston Scientific, Edwards Lifesciences, GE Healthcare, Medtronic and St Jude Medical. A M Pereira received consultancy fees from Pfizer, and R A Feelders from Novartis. The remaining authors have no conflict of interest.

Funding

K H Yiu is financially supported by a research grant from the Hong Kong Heart Foundation.

Acknowledgements

We thank Drs Arnold C T Ng, Tomasz G Witkowski, See Hooi Ewe, and Dominique Auger at the Department of Cardiology, Leiden University Medical Center, for the help provided in data collection and Prof. Hung Fat Tse at the Department of Medicine, University of Hong Kong, for reviewing the manuscript.

www.eje-online.org
References


20. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellicka PA, Picard MH, Roman MJ, Seward JB, Shaeenwe JS, Solomon SD, Spencer KT, Sutton MS & Stewart WJ. Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *Journal of the American Society of Echocardiography* 2005 18 1440–1463. (doi:10.1016/j.echo.2005.10.005)


Received 8 July 2011
Revised version received 19 September 2011
Accepted 17 October 2011

www.eje-online.org